Literature DB >> 33483114

Estimated Intelligence Moderates Cognitive Processing Therapy Outcome for Posttraumatic Stress Symptoms.

Brian P Marx1, Johanna Thompson-Hollands2, Daniel J Lee2, Patricia A Resick3, Denise M Sloan2.   

Abstract

Although patient intelligence may be an important determinant of the degree to which individuals may comprehend, comply with, and ultimately benefit from trauma-focused treatment, no prior studies have examined the impact of patient intelligence on benefit from psychotherapies for PTSD. We investigated the degree to which educational achievement, often used as a proxy for intelligence, and estimated full scale intelligence quotient (FSIQ) scores themselves moderated treatment outcomes for two effective psychotherapies for PTSD: Cognitive Processing Therapy (CPT) and Written Exposure Therapy (WET). Participants, 126 treatment-seeking adults with PTSD (52% male; mean age = 43.9, SD = 14.6), were equally randomized to CPT and WET; PTSD symptom severity was measured at baseline and 6-, 12-, 24-, 36-, and 60-weeks following the first treatment session. Multilevel models revealed that participants with higher FSIQ scores experienced significantly greater PTSD symptom reduction through the 24-week assessment in CPT but not WET; this effect did not persist through the 60-week assessment. Educational achievement did not moderate symptom change through either 24- or 60-weeks. Individuals with higher FSIQ who are treated with CPT may experience greater symptom improvement in the early stages of recovery.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  PTSD; cognitive-behavioral treatment; moderators; trauma

Year:  2020        PMID: 33483114     DOI: 10.1016/j.beth.2020.03.008

Source DB:  PubMed          Journal:  Behav Ther        ISSN: 0005-7894


  1 in total

1.  Sudden Gains in Two Trauma-Focused Treatments for Posttraumatic Stress Disorder.

Authors:  Denise M Sloan; Johanna Thompson-Hollands; Adele M Hayes; Daniel J Lee; Elizabeth Alpert; Brian P Marx
Journal:  Behav Ther       Date:  2021-08-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.